{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T08:04:50Z","timestamp":1765181090656,"version":"3.46.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>Chemotherapy interruptions are a frequent event during treatment of solid tumors and have been associated with adverse survival outcomes. Our objective was to determine the impact of intercycle delay during first-line systemic chemotherapy on survival in patients with metastatic (stage IVB) or recurrent cervical cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      A retrospective cohort study identified patients with metastatic or recurrent cervical cancer treated at our institutions. Demographics, clinicopathologic information, first-line chemotherapy regimens with associated intercycle delays, and outcome measures were abstracted from medical records. Delays were categorized as modifiable (social determinants of health, logistics, treatment break) or nonmodifiable (cytopenias, organ dysfunction, chemotherapy reaction, infection, ECOG status). Data were analyzed using descriptive statistics, Kaplan-Meier survival estimate, and log-rank tests to calculate significance (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Two hundred ten patients were evaluable for this study. 178 (85%) had at least one intercycle delay. One thousand eight hundred seventy-three chemotherapy cycles were completed with 701 (37%) delays. There was an equal proportion of modifiable (352\/701) and nonmodifiable (349\/701) delays. Patients with one or more intercycle delay had a longer median PFS (13 mo, IQR: 7 to 24) compared with those without delays (8 mo, IQR: 4 to 17),\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.042. PFS stratified by subgroups revealed patients with modifiable delays as having improved PFS (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.036) and nonmodifiable subgroup trending towards improved PFS (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.058) compared with patients with no delays. There was no PFS difference between the modifiable and nonmodifiable subgroups and no overall survival differences.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Intercycle delays during first-line systemic chemotherapy for metastatic or recurrent cervical cancer do not have an adverse effect on survival.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/coc.0000000000001279","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T08:00:14Z","timestamp":1765180814000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Interruptions in Chemotherapy on Survival for Patients With Metastatic or Recurrent Cervical Cancer"],"prefix":"10.1097","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7505-4837","authenticated-orcid":false,"given":"Risha","family":"Sinha","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Division of Gynecologic Oncology"}]},{"given":"Arianna","family":"Portmann-Baracco","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, TX"}]},{"given":"April R.","family":"Gorman","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, TX"}]},{"given":"Elizabeth C.","family":"Stock","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Division of Gynecologic Oncology"}]},{"given":"Steven Blaine","family":"Holloway","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Division of Gynecologic Oncology"}]},{"given":"David S.","family":"Miller","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Division of Gynecologic Oncology"}]},{"given":"Jayanthi S.","family":"Lea","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Division of Gynecologic Oncology"}]}],"member":"276","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"key":"R1-20251208","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N Engl J Med"},{"key":"R2-20251208","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(23)02405-4","article-title":"Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial","volume":"403","author":"Oaknin","year":"2024","journal-title":"Lancet"},{"key":"R3-20251208","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMoa2112187","article-title":"Survival with cemiplimab in recurrent cervical cancer","volume":"386","author":"Tewari","year":"2022","journal-title":"N Engl J Med"},{"key":"R4-20251208","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S0140-6736(17)31607-0","article-title":"Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)","volume":"390","author":"Tewari","year":"2017","journal-title":"Lancet"},{"key":"R5-20251208","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.annonc.2024.10.002","article-title":"Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study","volume":"36","author":"Lorusso","year":"2025","journal-title":"Ann Oncol"},{"key":"R6-20251208","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa2313811","article-title":"Tisotumab vedotin as second- or third-line therapy for recurrent cervical cancer","volume":"391","author":"Vergote","year":"2024","journal-title":"N Engl J Med"},{"key":"R7-20251208","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"R8-20251208","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1056\/NEJMra2404457","article-title":"Cervical cancer","volume":"392","author":"Tewari","year":"2025","journal-title":"N Engl J Med"},{"key":"R9-20251208","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S1701-2163(16)34101-9","article-title":"The significance of duration of chemotherapy interruptions due to interval surgery in ovarian cancer patients treated with neoadjuvant chemotherapy","volume":"31","author":"Le","year":"2009","journal-title":"J Obstet Gynaecol Canada"},{"key":"R10-20251208","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ygyno.2020.04.048","article-title":"Prolonged interruption of chemotherapy in patients undergoing delayed debulking surgery for advanced high grade serous ovarian cancer is associated with a worse prognosis","volume":"158","author":"Searle","year":"2020","journal-title":"Gynecol Oncol"},{"key":"R11-20251208","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jinf.2014.10.008","article-title":"The association between infections and chemotherapy interruptions among cancer patients: Prospective cohort study","volume":"70","author":"Taha","year":"2015","journal-title":"J Infect"},{"key":"R12-20251208","doi-asserted-by":"crossref","first-page":"m4087","DOI":"10.1136\/bmj.m4087","article-title":"Mortality due to cancer treatment delay: systematic review and meta-analysis","volume":"371","author":"Hanna","year":"2020","journal-title":"BMJ"},{"key":"R13-20251208","doi-asserted-by":"crossref","first-page":"4","DOI":"10.22514\/ejgo.2024.043","article-title":"Association between delayed initiation of treatment indications and survival in patients with cervical cancer: a systematic review and meta-analysis","volume":"45","author":"Shimels","year":"2024","journal-title":"Eur J Gynaecol Oncol"},{"key":"R14-20251208","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/cncr.27652","article-title":"The effect of treatment time in locally advanced cervical cancer in the era of concurrent chemoradiotherapy","volume":"119","author":"Song","year":"2012","journal-title":"Cancer"},{"key":"R15-20251208","first-page":"447","article-title":"Locally advanced cervical cancer: outcomes with variable adherence to treatment","volume":"41","author":"Manders","year":"2018","journal-title":"Am J Clin Oncol Cancer Clin Trials"},{"key":"R16-20251208","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"A metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inf"},{"key":"R18-20251208","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ygyno.2011.10.003","article-title":"Effect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancer","volume":"124","author":"Nagel","year":"2012","journal-title":"Gynecol Oncol"},{"key":"R19-20251208","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1097\/IGC.0000000000000537","article-title":"Treatment compliance and outcomes for women with locoregionally advanced cervical cancer treated in a safety net health system","volume":"25","author":"Hsieh","year":"2015","journal-title":"Int J Gynecol Cancer"},{"key":"R20-20251208","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/JTO.0b013e3181c3f5f7","article-title":"Intercycle delays during chemotherapy of non-small cell lung cancer in a health care resource-constrained setting and their effect on overall survival","volume":"5","author":"Singh","year":"2010","journal-title":"J Thorac Oncol"},{"key":"R21-20251208","doi-asserted-by":"crossref","first-page":"114301","DOI":"10.1016\/j.ejca.2024.114301","article-title":"The impact of inter-cycle treatment delays on 5-year all-cause mortality in early-stage breast cancer: a retrospective cohort study","volume":"210","author":"Steventon","year":"2024","journal-title":"Eur J Cancer"},{"key":"R22-20251208","doi-asserted-by":"crossref","first-page":"e1532","DOI":"10.1093\/oncolo\/oyae201","article-title":"The impact of inter-cycle treatment delays on overall survival in patients with advanced-stage ovarian cancer","volume":"29","author":"Steventon","year":"2024","journal-title":"Oncologist"},{"key":"R23-20251208","doi-asserted-by":"crossref","first-page":"908","DOI":"10.3390\/curroncol30010069","article-title":"Real-life effectivity of dose intensity reduction of first-line mFOLFIRI-based treatment of metastatic colorectal cancers: sometimes less is more","volume":"30","author":"P\u00e9csi","year":"2023","journal-title":"Curr Oncol"},{"key":"R24-20251208","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1586\/14737140.8.2.227","article-title":"Supportive care for women with gynecologic cancers","volume":"8","author":"Chase","year":"2008","journal-title":"Expert Rev Anticancer Ther"},{"key":"R25-20251208","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ogc.2018.10.001","article-title":"Palliative care in gynecologic oncology","volume":"46","author":"Mullen","year":"2019","journal-title":"Obstet Gynecol Clin North Am"},{"key":"R26-20251208","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1056\/NEJMoa1000678","article-title":"Early palliative care for patients with metastatic non-small-cell lung cancer","volume":"363","author":"Temel","year":"2010","journal-title":"N Engl J Med"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0000000000001279","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T08:00:17Z","timestamp":1765180817000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0000000000001279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":25,"URL":"https:\/\/doi.org\/10.1097\/coc.0000000000001279","relation":{},"ISSN":["0277-3732","1537-453X"],"issn-type":[{"value":"0277-3732","type":"print"},{"value":"1537-453X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]},"assertion":[{"value":"2025-10-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}